Högler Wolfgang, Linglart Agnès, Petryk Anna, Kishnani Priya S, Seefried Lothar, Fang Shona, Rockman-Greenberg Cheryl, Ozono Keiichi, Dahir Kathryn, Martos-Moreno Gabriel Ángel
Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, Austria.
Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.
Endocr Connect. 2023 Apr 25;12(5). doi: 10.1530/EC-22-0240. Print 2023 May 1.
Hypophosphatasia, an inborn error of metabolism characterized by impaired bone mineralization, can affect growth. This study evaluated relationships between anthropometric parameters (height, weight, and body mass index) and clinical manifestations of hypophosphatasia in children.
Data from children (aged <18 years) with hypophosphatasia were analyzed from the observational Global Hypophosphatasia Registry.
Anthropometric parameters were evaluated by age group (<2 years and ≥2 years) at assessment. The frequency of hypophosphatasia manifestations was compared between children with short stature (< percentile) and those with normal stature.
This analysis included 215 children (54.4% girls). Short stature presented in 16.1% of children aged <2 years and 20.4% of those aged ≥2 years at assessment. Among those with available data (n = 62), height was below the target height (mean: -0.66 standard deviations). Substantial worsening of growth (mean delta height z score: -1.45; delta weight z score: -0.68) occurred before 2 years of age, while in those aged ≥2 years, anthropometric trajectories were maintained (delta height z score: 0.08; delta weight z score: 0.13). Broad-ranging hypophosphatasia manifestations (beyond dental) were observed in most children.
Short stature was not a consistent characteristic of children with hypophosphatasia, but growth impairment was observed in those aged <2 years, indicating that hypophosphatasia might affect growth plate activity during infancy. In addition, a broad range of clinical manifestations occurred in those above and below the third percentile for height, suggesting that height alone may not accurately reflect hypophosphatasia disease burden and that weight is less affected than longitudinal growth.
低磷酸酯酶症是一种以骨矿化受损为特征的先天性代谢紊乱疾病,可影响生长发育。本研究评估了儿童低磷酸酯酶症的人体测量参数(身高、体重和体重指数)与临床表现之间的关系。
从观察性全球低磷酸酯酶症注册中心分析了低磷酸酯酶症儿童(年龄<18岁)的数据。
在评估时按年龄组(<2岁和≥2岁)评估人体测量参数。比较身材矮小(<百分位数)儿童和身材正常儿童低磷酸酯酶症表现的频率。
该分析纳入了215名儿童(54.4%为女孩)。在评估时,16.1%的<2岁儿童和20.4%的≥2岁儿童身材矮小。在有可用数据的儿童中(n = 62),身高低于目标身高(平均:-0.66标准差)。生长发育在2岁前显著恶化(平均身高z评分变化:-1.45;体重z评分变化:-0.68),而在≥2岁的儿童中,人体测量轨迹保持稳定(身高z评分变化:0.08;体重z评分变化:0.13)。大多数儿童观察到广泛的低磷酸酯酶症表现(除牙齿外)。
身材矮小并非低磷酸酯酶症儿童的一致特征,但在<2岁的儿童中观察到生长发育受损,这表明低磷酸酯酶症可能影响婴儿期的生长板活动。此外,身高在第三百分位数以上和以下的儿童均出现广泛的临床表现,这表明仅身高可能无法准确反映低磷酸酯酶症的疾病负担,且体重受影响小于纵向生长。